Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales

wsj.com/business/earnings/novo-nordisk-cuts-guidance-as-copycat-versions-of-ozempic-hit-sales-53df8b8a

The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, particularly in the U.S.

This story appeared on wsj.com, 2025-05-07 06:13:00.
The Entire Business World on a Single Page. Free to Use →